Cutaneous graft-versus-host disease: A guide for the dermatologist

Dermatology

Volumn 216, Issue 4, 2008, Pages 287-304

  Häusermann, Peter ^a   Walter, Roland B ^c   Halter, Jörg ^a   Biedermann, Barbara C ^a,b   Tichelli, André ^a   Itin, Peter ^a   Gratwohl, Alois ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b University Hospital Bruderholz   (Switzerland)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Dermatopathology; Graft versus host disease, cutaneous; Hematopoietic stem cell transplantation; Lichenoid dermatitis

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; CYTOKERATIN; DACLIZUMAB; ETANERCEPT; GAMMA INTERFERON; HLA ANTIGEN; INFLIXIMAB; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PENTOSTATIN; RAPAMYCIN; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VISILIZUMAB;

APOPTOSIS; CELL PROLIFERATION; CLINICAL FEATURE; EPITHELIUM CELL; GASTROINTESTINAL TRACT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOLOGY; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENCE; LICHENOID; MORBIDITY; MORTALITY; NOTE; OUTPATIENT; PRIORITY JOURNAL; PUVA; QUALITY OF LIFE; SCLERODERMA; SKIN GRAFT;

ANIMALS; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 43049123472     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000113941     Document Type: Note

References (99)

1. Thomas ED: A history of haemopoietic cell transplantation. Br J Haematol 1999;105:330-339.
2. Lorenz E, Congdon CC, Uphoff D: Modification of acute irradiation injury in mice and guinea-pigs by bone marrow injections. Radiology 1952;58:863-877.
3. Congdon CC, Uphoff D, Lorenz E: Modification of acute irradiation injury in mice and guinea-pigs by injection of bone marrow: a histopathologic study. J Natl Cancer Inst 1952;13:73-107.
4. Jacobson LO, Simmons EL, Marks EK, Eldredge JH: Recovery from irradiation injury. Science 1951;113:510-511.
5. Jacobson LO, Simmons EL, Marks EK, Gaston EO, Robson MJ, Eldredge JH: Further studies on recovery from radiation injury. J Lab Clin Med 1951;37:683-697.
6. Ford CE, Hamerton JL, Barnes DWH, Lou tit JF: Cytological identification of radiation-chimaeras. Nature 1956;177:452-454.
7. Thomas ED, Lochte HL, Cannon JH: Supralethal whole body irradiation and isologous marrow transplantation in man. J Clin Invest 1959;38:1709-1716.
8. Mathé G, Amiel JL, Schwarzenberg L, Catton A, Schneider M: Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res 1965;25:1525-1531.
9. Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA: Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968;ii:1366-1369.
10. Appelbaum FR: The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer. CA Cancer J Clin 1996;46:142-164.
11. Copelan EA: Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813-1826.
12. Slatter MA, Gennery AR: Umbilical cord stem cell transplantation for primary immunodeficiencies. Expert Opin Biol Ther 2006;6:555-565.
13. Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori J, Massenkeil G, Pedrazzoli P, Zambelli A, Bay JO, Françis S, Martino R, Bengala C, Brune M, Lenhoff S, Porcellini A, Falda M, Siena S, Demirer T, Niederwieser D, Ringden O: Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol 2006;17:1134-1140.
14. Gratwohl A, Baldomero H, Horisberger B, Schmid C, Passweg J, Urbano-Ispizua A: Current trends in hematopoietic stem cell transplantation in Europe. Blood 2002;100:2374-2386.
15. Gratwohl A: New developments in hematopoietic stem cell transplantation. Ther Umsch 2002;59:571-576.
16. Sullivan KM: Graft-versus-host disease;in Forman SJ, Blume KG, Thomas ED (eds): Bone Marrow Transplantation. Cambridge, Blackwell Scientific, 1994, pp 339-362.
17. Storek J, Gooley T, Witherspoon RP, Sullivan KM, Storb R: Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. Am J Hematol 1997;54:131-138.
18. Welniak LA, Blazar BR, Murphy WJ: Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007;25:139-170.
19. Hymes SR, Turner ML, Champlin RE, Couriel DR: Cutaneous manifestations of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2006;12:1101-1113.
20. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME: National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-956.
21. Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E, Moresi JM, Greenson J, Janin A, Martin PJ, McDonald G, Flowers ME, Turner M, Atkinson J, Lefkowitch J, Washington MK, Prieto VG, Kim SK, Argenyi Z, Diwan AH, Rashid A, Hiatt K, Couriel D, Schultz K, Hymes S, Vogelsang GB: Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. II. Pathology working group report. Biol Blood Marrow Transplant 2006;12:31-47.
22. Schultz KR, Miklos DB, Fowler D, Cooke K, Shizuru J, Zorn E, Holler E, Ferrara J, Shulman H, Lee SJ, Martin P, Filipovich AH, Flowers ME, Weisdorf D, Couriel D, Lachenbruch PA, Mittleman B, Vogelsang GB, Pavletic SZ: Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. III. Biomarker working group report. Biol Blood Marrow Transplant 2006;12:126-137.
23. Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, Turner ML, Akpek G, Gilman A, McDonald G, Schubert M, Berger A, Bross P, Chien JW, Couriel D, Dunn JP, Fall-Dickson J, Farrell A, Flowers ME, Greinix H, Hirschfeld S, Gerber L, Kim S, Knobler R, Lachenbruch PA, Miller FW, Mittleman B, Papadopoulos E, Parsons SK, Przepiorka D, Robinson M, Ward M, Reeve B, Rider LG, Shulman H, Schultz KR, Weisdorf D, Vogelsang GB: Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. IV. Response criteria working group report. Biol Blood Marrow Transplant 2006;12:252-266.
24. Couriel D, Carpenter PA, Cutler C, Bolanos-Meade J, Treister NS, Gea-Banacloche J, Shaughnessy P, Hymes S, Kim S, Wayne AS, Chien JW, Neumann J, Mitchell S, Syrjala K, Moravec CK, Abramovitz L, Liebermann J, Berger A, Gerber L, Schubert M, Filipovich AH, Weisdorf D, Schubert MM, Shulman H, Schultz K, Mittelman B, Pavletic S, Vogelsang GB, Martin PJ, Lee SJ, Flowers ME: Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. V. Ancillary therapy and supportive care working group report. Biol Blood Marrow Transplant 2006;12:375-396.
25. Martin PJ, Weisdorf D, Przepiorka D, Hirschfeld S, Farrell A, Rizzo JD, Foley R, Socie G, Carter S, Couriel D, Schultz KR, Flowers ME, Filipovich AH, Saliba R, Vogelsang GB, Pavletic SZ, Lee SJ: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. VI. Design of clinical trials working group report. Biol Blood Marrow Transplant 2006;12:491-505.
26. Marshall SR: Technology insight: ECP for the treatment of GVHD - can we offer selective immune control without generalized immunosuppression? Nat Clin Pract Oncol 2006;3:302-314.
27. Perez-Simon JA, Sanchez-Abarca I, Diez-Campelo M, Caballero D, San Miguel J: Chronic graft-versus-host disease: pathogenesis and clinical management. Drugs 2006;66:1041-1057.
28. Bolanos-Meade J: Update on the management of acute graft-versus-host disease. Curr Opin Oncol 2006;18:120-125.
29. Billingham RE: Reactions of grafts against their hosts. Science 1959;130:947-953.
30. Billingham RE: The biology of graft versus host reactions. Harvey Lec 1966-1967;62:21-78.
31. Korngold R, Sprent J: T cell subsets in graft versus host disease;in Deeg HJ, Ferrara J, Atkinson J (eds): Graft-versus-Host Disease: Immunobiology, Pathophysiology, and Treatment. New York, Dekker, 1990, pp 31-50.
32. Krensky AM, Weiss A, Crabtree G, Davis MM, Parham P: T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med 1990;322:510-517.
33. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM, Maris MB, Storb R: Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102:756-762.
34. Schaffer JV: The changing face of graft-versus-host disease. Semin Cutan Med Surg 2006;25:190-200.
35. Deeg HJ, Spitzer TR, Cottler-Fox M, Cahill R, Pickle LW: Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. Bone Marrow Transplant 1991;7:193-198.
36. Weisdorf DJ: Chronic graft-versus-host disease: where is promise for the future? Leukemia 2005;19:1532-1535.
37. Fraser CJ, Bhatia S, Ness K, Carter A, Francisco L, Arora M, Parker P, Forman S, Weisdorf D, Gurney JG, Baker KS: Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the bone marrow transplant survivor study. Blood 2006;108:2867-2873.
38. Lee SJ, Kim HT, Ho VT, Cutler C, Alyea EP, Soiffer RJ, Antin JH: Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant 2006;38:305-310.
39. Akpek G, Akpek CS, Vogelsang G: Clinical spectrum and therapeutic approaches to chronic graft-vs-host disease;in Ferrara J, Cooke K, Deeg HJ (eds): Graft-versus-Host Disease. New York, Dekker, 2005, pp 555-608.
40. Zhan Q, Signoretti S, Whitaker-Menezes D, Friedman TM, Korngold R, Murphy GF: Cytokeratin-15-positive basal epithelial cells targeted in graft-versus-host disease express a constitutive antiapoptotic phenotype. J Invest Dermatol 2007;127:106-115.
41. Zhou L, Askew D, Wu C, Gilliam AC: Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 2007;127:281-292.
42. Ferrara JLM, Cooke KR, Teshima T: The pathophysiology of graft-versus-host disease; in Ferrara JLM, Cooke KR, Deeg HJ (eds): Graft-versus-Host Disease. New York, Dekker, 2005, pp 1-34.
43. Hofmeister CC, Quinn A, Cooke KR, Stiff P, Nickoloff B, Ferrara JL: Graft-versus-host disease of the skin: life and death on the epidermal edge. Biol Blood Marrow Transplant 2004;10:366-372.
44. Hermanns-Le T, Paquet P, Piéard-Franchimont C, Arrese JE, Piéard GE: Regulatory function of factor-XIIIa-positive dendrocytes in incipient toxic epidermal necrolysis and graft-versus-host reaction: a hypothesis. Dermatology 1999;198:184-186.
45. Yoo YH, Park BS, Whitaker-Menezes D, Korngold R, Murphy GF: Dermal dendrocytes participate in the cellular pathology of experimental acute graft-versus-host disease. J Cutan Pathol 1998;25:426-434.
46. Couriel D, Caldera H, Champlin R, Komanduri K: Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 2004;101:1936-1946.
47. Dickinson AM, Wang XN, Sviland L, Vyth-Dreese FA, Jackson GH, Schumacher TN, Haanen JB, Mutis T, Goulmy E: In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 2002;8:410-414.
48. Gratwohl A, Hermans J, Niederwieser D, van Biezen A, van Houwelingen HC, Apperley J: Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants. Hematol J 2001;2:363-370.
49. Hess AD: Modulation of graft-versus-host disease: role of regulatory T lymphocytes. Biol Blood Marrow Transplant 2006;12:13-21.
50. Cutler C, Antin JH: Chronic graft-versus-host disease. Curr Opin Oncol 2006;18:126-131.
51. Sullivan KM: Graft-versus-host disease;in Blume KG, Forman SJ, Appelbaum FR (eds): Thomas' Hematopoietic Cell Transplantation, ed 3. Malden, Blackwell Publishing, 2004, pp 635-664.
52. Lawley TJ, Peck GL, Moutsopoulos HM, Gratwohl AA, Deisseroth AB: Scleroderma, Sjoren-like syndrome, and chronic graft-versus-host disease. Ann Intern Med 1977;87:707-709.
53. Gratwhol AA, Moutsopoulos HM, Chused TM, Akizuki M, Wolf RO, Sweet JB, Deisseroth AB: Sjören-type syndrome after allogeneic bone-marrow transplantation. Ann Intern Med 1977;87:703-706.
54. Higman MA, Vogelsang GB: Chronic graft versus host disease. Br J Haematol 2004;125:435-454.
55. Daneshpouy M, Socie G, Lemann M, Rivet J, Gluckman E, Janin A: Activated eosinophils in upper gastrointestinal tract of patients with graft-versus-host disease. Blood 2002;99:3033-3040.
56. Jacobsohn DA, Schechter T, Seshadri R, Thormann K, Duerst R, Kletzel M: Eosinophilia correlates with the presence or development of chronic graft-versus-host disease in children. Transplantation 2004;77:1096-1100.
57. Biedermann BC, Sahner S, Gregor M, Tsakiris DA, Jeanneret C, Pober JS, Gratwohl A: Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002;359:2078-2083.
58. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A, Avvedimento EV, Gabrielli A: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667-2676.
59. Zorn E: CD4+CD25+ regulatory T cells in human hematopoietic cell transplantation. Semin Cancer Biol 2006;16:150-159.
60. Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC, Matsui WH, Arai S, Fuchs EJ, Vogelsang GB, Jones RJ, Hess AD: Association of FOXP3 regulatory gene expression with graft-versus-host disease. Blood 2004;104:2187-2193.
61. Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, Bellucci R, Alyea EP, Antin JH, Soiffer RJ, Ritz J: Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005;106:2903-2911.
62. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R, Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz J, Alyea E: Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006;108:756-762.
63. Rowe V, Banovic T, MacDonald KP, Kuns R, Don AL, Morris ES, Burman AC, Bofinger HM, Clouston AD, Hill GR: Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood 2006;108:2485-2492.
64. Rappeport J, Mihm M, Reinherz E, Lopansri S, Parkman R: Acute graft-versus-host disease in recipients of bone-marrow transplants from identical twin donors. Lancet 1979;2:717-720.
65. Hess AD: The immunobiology of syngeneic/autologous graft-versus-host disease;in Ferrara JLM, Deeg HJ, Burakoff SJ (eds): Graft-versus-Host Disease, ed 2. New York, Dekker, 1997, pp 561-586.
66. Saurat JH: Cutaneous manifestations of graft-versus-host disease. Int J Dermatol 1981;20:249-256.
67. Itin PH, Lautenschlager S, Orth B, Rufli T, Gratwohl A: Skin manifestations of graft-versus-host reaction following bone marrow transplantation. Schweiz Med Wochenschr 1996;126:339-347.
68. Johnson ML, Farmer ER: Graft-versus-host reactions in dermatology. J Am Acad Dermatol 1998;38:369-392, quiz 393-396.
69. Aractingi S, Chosidow O: Cutaneous graft-versus-host disease. Arch Dermatol 1998;134:602-612.
70. Antin JA, Deeg HJ: Clinical spectrum of acute graft-vs-host disease;in Ferrara JL, Cooke KR, Deeg HJ (eds): Graft-versus-Host Disease. New York, Dekker, 2005, pp 369-381.
71. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED: 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-828.
72. Baselga E, Drolet BA, Segura AD, Leonardi CL, Esterly NB: Dermatomal lichenoid chronic graft-versus-host disease following varicella-zoster infection despite absence of viral genome. J Cutan Pathol 1996;23:576-581.
73. Schaffer JV, McNiff JM, Seropian S, Cooper DL, Bolognia JL: Lichen sclerosus and eosinophilic fasciitis as manifestations of chronic graft-versus-host disease: expanding the sclerodermoid spectrum. J Am Acad Dermatol 2005;53:591-601.
74. Spiryda LB, Laufer MR, Soiffer RJ, Antin JA: Graft-versus-host disease of the vulva and/or vagina: diagnosis and treatment. Biol Blood Marrow Transplant 2003;9:760-765.
75. Nagler R, Marmary Y, Krausz Y, Chisin R, Markitziu A, Nagler A: Major salivary gland dysfunction in human acute and chronic graft-versus-host disease (GVHD). Bone Marrow Transplant 1996;17:219-224.
76. Biedermann BC, Tsakiris DA, Gregor M, Pober JS, Gratwohl A: Combining altered levels of effector transcripts in circulating T cells with a marker of endothelial injury is specific for active graft-versus-host disease. Bone Marrow Transplant 2003;32:1077-1084.
77. Lerner KG, Kao GF, Storb R, Buckner CD, Clift RA, Thomas ED: Histopathology of graft-versus-host reaction (GVHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc 1974;6:367-371.
78. Sale GE, Shulman HM, Gallucci BB, Thomas ED: Young rete ridge keratinocytes are preferred targets in cutaneous graft-versus-host disease. Am J Pathol 1985;118:278-287.
79. Whitaker-Menezes D, Jones SC, Friedman TM, Korngold R, Murphy GF: An epithelial target site in experimental graft-versus-host disease and cytokine-mediated cytotoxicity is defined by cytokeratin 15 expression. Biol Blood Marrow Transplant 2003;9:559-570.
80. Lyle S, Christofidou-Solomidou M, Liu Y, Elder DE, Albelda S, Cotsarelis G: The c8/144b monoclonal antibody recognizes cytokeratin 15 and defines the location of human hair follicle stem cells. J Cell Sci 1998;111:3179-3188.
81. Heldal D, Brinch L, Evensen SA, Tjonnfjord GE, Aamodt G, Elgjo K, Sviland L: Skin biopsies for early diagnosis and prognosis of graft-versus-host disease in recipients of allogeneic stem cells from blood or bone marrow. Bone Marrow Transplant 2004;34:345-350.
82. Darmstadt GL, Donnenberg AD, Vogelsang GB, Farmer ER, Horn TD: Clinical, laboratory, and histopathologic indicators of the development of progressive acute graft-versus-host disease. J Invest Dermatol 1992;99:397-402.
83. Zhou Y, Barnett MJ, Rivers JK: Clinical significance of skin biopsies in the diagnosis and management of graft-versus-host disease in early postallogeneic bone marrow transplantation. Arch Dermatol 2000;136:717-721.
84. Kohler S, Hendrickson MR, Chao NJ, Smoller BR: Value of skin biopsies in assessing prognosis and progression of acute graft-versushost disease. Am J Surg Pathol 1997;21:988-996.
85. Bridge AT, Nelson RP Jr, Schwartz JE, Mirowski GW, Billings SD: Histological evaluation of acute mucocutaneous graft-versus-host disease in nonmyeloablative hematologic stem cell transplants with an observation predicting an increased risk of progression to chronic graft-versus-host disease. Am J Dermatopathol 2007;29:1-6.
86. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, Hackman R, Tsoi MS, Storb R, Thomas ED: Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-217.
87. Soiffer R: Graft manipulation to prevent graft-vs-host disease;in Ferrara JLM, Cooke KR, Deeg HJ (eds): Graft-versus-Host Disease, ed 3. New York, Dekker, 2005, pp 481-509.
88. Chao NJ, Holler E, Deeg HJ: Prophylaxis and treatment of acute graft-versus-host disease; in Ferrara JLM, Cooke KR, Deeg HJ (eds): Graft-versus-Host Disease, ed 3. New York, Dekker, 2005, pp 459-479.
89. Penas PF, Fernandez-Herrera J, Garcia-Diez A: Dermatologic treatment of cutaneous graft versus host disease. Am J Clin Dermatol 2004;5:403-416.
90. Giaccone L, Martin P, Carpenter P, Moravec C, Hooper H, Funke VA, Storb R, Flowers ME: Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease. Bone Marrow Transplant 2005;36:337-341.
91. Wetzig T, Sticherling M, Simon JC, Hegenbart U, Niederwieser D, Al-Ali HK: Medium dose long-wavelength ultraviolet a (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. Bone Marrow Transplant 2005;35:515-519.
92. Dall'Amico R, Messina C: Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Ther Apher 2002;6:296-304.
93. Bonanomi S, Balduzzi A, Tagliabue A, Biagi E, Rovelli A, Corti P, Crippa D, Uderzo C: Bath PUVA therapy in pediatric patients with drug-resistant cutaneous graft-versus-host disease. Bone Marrow Transplant 2001;28:631-632.
94. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-1441.
95. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, Marschall HU, Dlugosz A, Szakos A, Hassan Z, Omazic B, Aschan J, Barkholt L, Le Blanc K: Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006;81:1390-1397.
96. Horowitz MM: Uses and growth of hematopoietic cell transplantation;in Thomas ED, Blume KG, Forman S (eds): Hematopoietic Cell Transplantation. Cambridge, Blackwell Science, 1999, pp 12-18.
97. Shlomchik WD, Lee SJ, Couriel D, Pavletic SZ: Transplantation's greatest challenges: advances in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007;13(suppl 1):2-10.
98. Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY, Carabasi MH, Gale RP, Giralt S, Hale GA, Ilhan O, McCarthy PL, Socie G, Verdonck LF, Weisdorf DJ, Horowitz MM: Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002;100:406-414.
99. Andorsky DJ, Loberiza FR, Lee SJ: Pre-transplantation physical and mental functioning is strongly associated with self-reported recovery from stem cell transplantation. Bone Marrow Transplant 2006;37:889-895.